Breaking Finance News

Deutsche Bank issued a report on Alexion Pharma (NASDAQ:ALXN), upping its target price to $158.00 today

Alexion Pharma (NASDAQ:ALXN) had its price target upped to $158.00 by Deutsche Bank in an issued report issued 9/13/2017. The upped price target implies a potential upside of 0.10% from the company's previous stock price.

Having a price of $144.07, Alexion Pharma (NASDAQ:ALXN) traded 0.05% higher on the day. With the last stock price close up 16.01% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the date range. Alexion Pharma has recorded a 50-day average of $137.20 and a two hundred day average of $124.25. Volume of trade was down over the average, with 283,478 shares of ALXN changing hands under the typical 2,140,180

Performance Chart

Alexion Pharma (NASDAQ:ALXN)

With a total market value of $0, Alexion Pharma has 52 week low of $96.18 and a 52 week high of $149.34 with a P/E ratio of 62.51 .

In addition to Deutsche Bank reporting its target price, a total of 18 firms have reported on the stock. The consensus target price is $187.61 with 7 brokerages rating the stock a strong buy, 6 brokerages rating the stock a buy, 7 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

Brief Synopsis On Alexion Pharma (NASDAQ:ALXN)

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *